Porcaro Antonio Benito, Costantino Sonia, Montanaro Francesca, Baielli Alberto, Artoni Francesco, Serafin Emanuele, Roggero Luca, Brancelli Claudio, Franceschini Andrea, Princiotta Alessandro, Boldini Michele, Treccani Lorenzo, Bon Lorenzo De, Bianchi Alberto, Veccia Alessandro, Rizzetto Riccardo, Brunelli Matteo, Marco Vincenzo De, Siracusano Salvatore, Cerruto Maria Angela, Bertolo Riccardo Giuseppe, Antonelli Alessandro
Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Department of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Cent European J Urol. 2025;78(2):109-115. doi: 10.5173/ceju.2024.0170. Epub 2025 May 27.
The aim of this study was to evaluate the prognostic impact of favourable prostate cancer (PCa) pathology patterns through Briganti's 2012 nomogram and beyond EAU risk classes in patients treated with robotic surgery.
We analysed 757 patients from January 2013 to December 2021 with favourable pathology features (ISUP 1-3, pT2/pT3a, and pN0/x) and available follow-up. Pathologic features were scored from zero (ISUP 1 + pT2) to three (ISUP 3 + pT3a). Associations with Briganti's 2012 nomogram by EAU risk class were evaluated to determine the prognostic impact on PCa progression, defined as biochemical persistence/recurrence or loco-regional/metastatic recurrence.
Favourable pathology risk scores were most commonly grades one (49%) and two (30.95%), followed by zero (15.2%) and three (4.9%). After adjusting for EAU prognostic groups, higher nomogram scores were associated with increased risk scores of two and three. PCa progression occurred in 12.7% of cases after a mean follow-up of 92.1 months. Patients with recurrence had a worse prognosis as risk scores increased from one to three, even after adjustment for Briganti's 2012 nomogram by EAU class.
Favourable pathology risk scores, grouped by Briganti's 2012 and EAU nomograms, impact prognosis. As scores increase, the likelihood of disease progression rises, potentially influencing treatment strategies.
本研究旨在通过布里甘蒂2012年列线图以及超越欧洲泌尿外科协会(EAU)风险分级,评估有利前列腺癌(PCa)病理模式对接受机器人手术患者的预后影响。
我们分析了2013年1月至2021年12月期间757例具有有利病理特征(国际泌尿病理学会[ISUP] 1 - 3级、pT2/pT3a和pN0/x)且有可用随访资料的患者。病理特征从零分(ISUP 1 + pT2)到三分(ISUP 3 + pT3a)进行评分。评估与EAU风险分级的布里甘蒂2012年列线图的相关性,以确定对PCa进展的预后影响,PCa进展定义为生化持续/复发或局部/远处复发。
有利病理风险评分最常见的是一级(49%)和二级(30.95%),其次是零级(15.2%)和三级(4.9%)。在调整EAU预后组后,较高的列线图评分与二级和三级风险评分增加相关。平均随访92.1个月后,12.7%的病例发生了PCa进展。复发患者的预后较差,随着风险评分从一级增加到三级,即使在根据EAU分级对布里甘蒂2012年列线图进行调整后也是如此。
根据布里甘蒂2012年和EAU列线图分组的有利病理风险评分影响预后。随着评分增加,疾病进展的可能性上升,可能会影响治疗策略。